XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT).

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 04 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Jun 2014 Planned End Date changed from 1 Feb 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
    • 07 Oct 2013 Planned end date changed from 1 Oct 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top